Login to Your Account

Gilead's HIV Franchise Strong; Earnings Top Analyst Estimates

By Randall Osborne

Monday, August 2, 2004
Gilead Sciences Inc. walloped forecasts by posting second-quarter net income that was up 11 percent, thanks to the briskly selling HIV treatment Viread and the hepatitis B therapy Hepsera. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription